Agenus (AGEN) Expected to Release Earnings on Thursday

Agenus (NASDAQ:AGEN) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agenus to announce earnings of $0.02 per share and revenue of $28.20 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. The business had revenue of $34.52 million during the quarter, compared to the consensus estimate of $34.00 million. On average, analysts expect Agenus to post ($0.30) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Agenus Stock Up 7.2%

Shares of NASDAQ:AGEN opened at $7.13 on Thursday. The stock has a market capitalization of $322.01 million, a P/E ratio of 2.76 and a beta of 1.31. Agenus has a 52 week low of $2.71 and a 52 week high of $10.31. The firm has a fifty day simple moving average of $7.63 and a two-hundred day simple moving average of $4.91.

Analyst Ratings Changes

AGEN has been the subject of a number of recent research reports. Rodman & Renshaw assumed coverage on Agenus in a report on Monday, September 28th. They issued a “buy” rating and a $19.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Wall Street Zen lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.50.

About Agenus

Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.